<DOC>
	<DOCNO>NCT00838162</DOCNO>
	<brief_summary>The purpose study evaluate antiviral activity measure change viral load baseline 14 day follow initiation treatment 4 different dose regimen TMC310911 co-administered ritonavir .</brief_summary>
	<brief_title>A Study Determine Antiviral Activity TMC310911 When Administered With Ritonavir Treatment-Naive Human Immunodeficiency Virus - Type 1 ( HIV-1 ) Infected Patients</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) randomize ( study medication assign chance ) study treatment-naive human immunodeficiency virus type 1 ( HIV-1 ) -infected participant ( participant treat therapeutic HIV vaccine within 1 year prior enrollment never treat antiretroviral [ ARV ] medication indicate treatment HIV-infection ARVs treatment hepatitis B infection anti-HIV activity prior screen ) . In study approximately 32 participant enrol randomly assign receive 4 different dose regimen co-administered ritonavir ( 8 participant dose regimen ) . The trial consist screen period ( maximum 6 week ) , treatment period TMC310911 ( 2 week ) , follow-up period ( 4 week ) . Safety evaluation include assessment adverse event , clinical laboratory test , vital sign measurement , physical examination electrocardiograms .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Documented human immunodeficiency virus type 1 ( HIV1 ) infection least 6 month prior screen date Participant treat therapeutic HIV vaccine within 1 year prior enrolment never treat antiretroviral ( ARV ) medication indicate treatment HIV infection ARVs treatment hepatitis Binfection antiHIV activity Participant agree start antiretroviral therapy ( ART ) baseline visit Able comply protocol requirement good accessible vein HIV1 plasma viral load screen visit 5,000 HIV1 Ribonucleic acid copies/mL CD4+ cell count 200 cells/mm3 screen HIV2 infect participant and/or participant active chronic hepatorenal disease Life expectancy le 6 month Documented acute ( primary ) HIV1 infection Preexisting protease inhibitor ( PI ) medication resistance Any currently active Acquired Immunodeficiency Syndrome ( AIDS ) define illness Any active clinically significant disease finding screen medical history physical examination investigator 's opinion , would compromise outcome study Any confirm grade 3 4 toxicity accord Division AIDS ( DAIDS ) grade scale screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Human immunodeficiency virus type 1</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV-1 treatment-naive</keyword>
	<keyword>TMC310911</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Antiviral Activity</keyword>
	<keyword>HIV Infections</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>